Zydus Lifesciences inches up on launching REVAHALE
Zydus Lifesciences is currently trading at Rs. 1121.10, up by 0.40 points or 0.04% from its previous closing of Rs. 1120.70 on the BSE.
The scrip opened at Rs. 1115.35 and has touched a high and low of Rs. 1129.50 and Rs. 1115.35 respectively. So far 8806 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1181.00 on 08-Jul-2026 and a 52 week low of Rs. 835.85 on 02-Apr-2026.
Last one week high and low of the scrip stood at Rs. 1132.30 and Rs. 1093.30 respectively. The current market cap of the company is Rs. 112019.68 crore.
The promoters holding in the company stood at 75.01%, while Institutions and Non-Institutions held 18.15% and 6.83% respectively.
Zydus Lifesciences has launched REVAHALE (Revefenacin), India’s first once-daily nebulised Long-Acting Muscarinic Antagonist (LAMA) indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).
REVAHALE is the first and only LAMA available in India that combines once-daily dosing with nebulized administration, offering a new treatment option for COPD patients who require nebulised therapy. Designed to provide sustained 24-hour bronchodilation with a single daily dose, REVAHALE addresses important challenges associated with inhaler-dependent therapies, particularly among elderly patients and those with severe respiratory impairment.
COPD remains a significant public health challenge in India and is a leading cause of morbidity and mortality. While inhaled bronchodilator therapies have transformed disease management, many patients continue to experience difficulties using handheld inhalers, cognitive limitations, severe breathlessness, or an inability to generate sufficient inspiratory effort for effective drug delivery. REVAHALE has been developed to address these unmet needs through a convenient nebulised delivery platform that reduces dependence on inhalation technique and inspiratory flow. The therapy is compatible with standard jet nebulisers, providing flexibility and ease of use for patients and caregivers.
